Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist

Human Psychopharmacology

Volumn 24, Issue 6, 2009, Pages 437-446

  Piǩulić, Danijela ^a   Olver, James S ^a   Maruff, Paul ^b   Norman, Trevor R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CogState ^*  (Australia)

Author keywords

Buspirone; Cognition; Schizophrenia; Serotonin; Treatment

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST;

ACUTE DRUG ADMINISTRATION; ADJUVANT THERAPY; ADULT; ARTICLE; ATTENTION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEMALE; HUMAN; MALE; MENTAL PERFORMANCE; NAUSEA; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; VERBAL MEMORY;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BUSPIRONE; CHRONIC DISEASE; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA; SEROTONIN AGONISTS; TIME FACTORS; YOUNG ADULT;

EID: 70349544018     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1046     Document Type: Article

References (47)

1. Aleman A, Hijman R, De Haan EHF, Kahn RS. 1999. Memory impairment in schizophrenia: a meta-analysis. Am J Psych 156: 1358-1366.
2. Andreasen NC. 1983. The Scale for the Assessment of Negative Symptoms (SANS). The University of Iowa: Iowa City, Iowa.
3. Barnes TR. 1989. A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
4. Brandt J. 1991. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clinical Neuropsychologist 5: 125-142.
5. Brody D, Adler LA, Kim T, Angrist B, Rotrosen J. 1990. Effects of buspirone in seven schizophrenic subjects. J Clin Psychopharmacol 10: 68-69.
6. Buchanan RW, Summerfelt A, Tek C, Gold J. 2003. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59: 29-33.
7. Coull JT. 1998. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog Neurobiol 55: 343-361.
8. Darby D, Maruff P, Collie A, Mcstephen M. 2002. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology 59: 1042-1046.
9. Falleti MG, Maruff P, Collie A, Darby DG, Mcstephen M. 2003. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res 12: 265-274.
10. Gobert A, Rivet JM, Cistarelli L, Melon C, Millan MJ. 1999. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 93: 1251-1262.
11. Goff DC, Midha KK, Brotman AW, Mccormick S, Waites M, Amico ET. 1991. An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193-197.
12. Gold JM. 2004. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 72: 21-28.
13. Golden C, Freshwater SM. 2002. Stroop colour word test: a manual for clinical and experimental uses. Stoelting: Wood Dale IL.
14. Green JF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right Stuff"? Schizophr Bull 26: 119-136.
15. Heinrichs RW, Zakzanis KK. 1998. Neurocognitive deficits in schizophrenia: a quantitative review of the evidence. Neuropsychology 12: 426-445.
16. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'laughlin IA, Meltzer HY. 2001. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
17. Ichikawa J, Meltzer HY. 1999. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291: 1227-1232.
18. Jarskog LF, Miyamoto S, Lieberman JA. 2007. Schizophrenia: new pathological insights and therapies. Ann Rev Med 58: 49-61.
19. Johnson-Selfridge M, Zalewski C. 2001. Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizophr Bull 27: 305-316.
20. Kay SR, Opler LA, Fiszbein A. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
21. Lee J, Park S. 2005. Working memory impairments in schizophrenia: A meta-analysis. J Abnorm Psych 114: 599-611.
22. Li XM, Perry KW, Wong DT, Bymaster FP. 1998. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacol (Berl) 136: 153-161.
23. Mcgurk SR, Carter C, Goldman R, et al. 2005. the effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry 1013-1016.
24. Meltzer HY, Mcgurk SR. 1999. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
25. Millan MJ. 2000. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295: 853-861.
26. Millan MJ, Lejeune F, Gobert A. 2000. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114-138.
27. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104.
28. Murphy BL, Arnsten AFT, Goldman-Rakic PS, Roth RH. 1996a. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci U S A 93: 1325-1329.
29. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C. 2005. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8: 341-356.
30. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 790-812.
31. Piškulic D, Olver JS, Norman TR, Maruff P. 2007. Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res 150: 111-121.
32. Sadock BJ, Sadock VA. 2007. Kaplan and Sadock's synopsis of psychiatry: Behavioural sciences/clinical psychiatry, Wolters Kluwer Health.
33. Sakaue M, Somboonthum P, Nishihara B, et al. 2000. Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129: 1028-1034.
34. Sawaguchi T, Goldman-Rakic PS. 1991. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947-950.
35. Silbert BS, Maruff P, Evered LA, et al. 2004. Detection of cognitive decline after coronary surgery: a comparison of computerized and conventional tests. Br J Anaesth 92: 814-820.
36. Simpson GM, Angus JW. 1970. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
37. Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. 2001. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol 21: 454-455.
38. Strzelczyk AA, Jaronczyk M, Chilmonczyk Z, Mazurek AP, Chojnacka-Wojcik E, Sylte I. 2004. Intrinsic activity and comparative molecular dynamics of buspirone analogues at the 5-HT(1A) receptors. Biochem Pharmacol 67: 2219-2230.
39. Sumiyoshi T, Jayathilake K, Roy A, Meltzer HY. 2006. Effect of buspirone, a serotonin partial agonist, on cognitive function in schizophrenia. Int J Neuropsychopharmacol 9: 248.
40. Sumiyoshi T, Matsui M, Nohara S, et al. 2001b. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722-1725.
41. Sumiyoshi T, Matsui M, Yamashita I, et al. 2001a. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49: 861-868.
42. Sumiyoshi T, Matsui M, Yamashita I, et al. 2000. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20: 386-388.
43. Sumiyoshi T, Meltzer HY. 2004. Serotonin 1A receptors in memory function. Am J Psychiatry 161: 1505; author reply 1505-1506.
44. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. 2007. Effect of buspirone, a serotonin(1A) partial agonist, on cognitive function in schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res 95: 158-168.
45. Tanda G, Carboni E, Frau R, Di Chiara G. 1994. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacol (Berl) 115: 285-288.
46. Weinberger DR, Lipska BK. 1995. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16: 87-110.
47. Yasuno F, Suhara T, Nakayama T, et al. 2003. Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry 160: 334-340.